Dr. Druta earned her MD degree from the University of Medicine and Pharmacy Carol Davila, Romainia. She completed an Internal Medicine Residency and Hematology/Medical Oncology Fellowship at the University of South Florida at Moffitt Cancer Center. Dr. Druta most recently completed a Sarcoma Medical Oncology Fellowship (Willie Tichenor Sarcoma Fellowship) at MD Anderson Cancer Center.
Dr. Druta's clinical interest is in the development of clinical trials focusing on targeted therapeutics specific to sarcoma patients. Her research interest is in the translational aspects of sarcoma biology focusing specifically on Well-differentiated/Differential Liposarcoma and Leiomyosarcoma.
Education & Training
Board Certification:
Internal Medicine
Internal Medicine
Fellowship:
H. Lee Moffitt Cancer Center - Hematology and Medical Oncology
MD Anderson Cancer Center - Sarcoma Medical Oncology
Residency:
University of South Florida - Internal Medicine
Medical School:
University of Medicine and Pharmacy Carol Davilla - MD
CLINICAL TRIAL 19414
A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: Talimogene Laherparepvec (OncoVEX); Talimogene laherparepvec 10^6 PFU (Talimogene Laherparepvec); Talimogene laherparepvec 10^8 PFU (Talimogene Laherparepvec)
Open
CLINICAL TRIAL 20251
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 Study)
Condition: Immunotherapy
Intervention: ADP-A2M4 (); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open
CLINICAL TRIAL 19487
A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma
Condition: Sarcoma
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); azacitidine (5-azacitidine)
Open
CLINICAL TRIAL 20837
Envasarc: A Pivitol Trial of Envafolimab, and Envafolimab in Combination with Ipilimumab, in Patients with Advanced or Metastatic Undifferentiated Pleomorphic Sarcoma or Myxofibrosarcoma Who Have Progressed on Prior Chemotherapy
Condition: Sarcoma
Intervention: Envafolimab (); Ipilimumab (); Yervoy (Ipilimumab)
Open
CLINICAL TRIAL 19580
A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BA3011 (); BMS-936558 (Nivolumab); Nivolumab (Opdivo)
Open
CLINICAL TRIAL 21029
A Multicenter Phase II Trial of Paclitaxel with and without Nivolumab in Taxane Naïve, and Nivolumab and Cabozantinib in Taxane Pre-treated Subjects with Angiosarcoma
Condition: Sarcoma
Intervention: BMS-936558 (Nivolumab); Cabozantinib (XL 184); Nivolumab (Opdivo); Taxol (paclitaxel); paclitaxel ()
Open
If you believe you are eligible for one of these trials or studies, please call 813-745-6100 or toll-free 1-800-679-0775.
Lewis JH, Gelderblom H, van de Sande M, Stacchiotti S, Healey JH, Tap WD, Wagner AJ, Pousa AL, Druta M, Lin CC, Baba HA, Choi Y, Wang Q, Shuster DE, Bauer S. Pexidartinib Long-Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors. Oncologist. 2021 May.26(5):e863-e873. Pubmedid: 33289960. Pmcid: PMC8100574.
Robinson LA, Babacan NA, Tanvetyanon T, Henderson-Jackson E, Bui MM, Druta M. Results of treating primary pulmonary sarcomas and pulmonary carcinosarcomas. J Thorac Cardiovasc Surg. 2021 Jul.162(1):274-284. Pubmedid: 32711968.
Afiat TP, Johns C, Smith J, Kis B, Druta M. Adrenal crisis and death following transarterial chemoembolization of sarcoma liver metastases. Clin Imaging. 2021 Jan.69:79-81. Pubmedid: 32693227.
Lee DH, Armanious M, Huang J, Jeong D, Druta M, Fradley MG. Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge. J Oncol Pharm Pract. 2020 Sep.26(6):1544-1548. Pubmedid: 32089073.
Krzyston H, Morse B, Deperalta D, Rishi A, Kayaleh R, El-Haddad G, Smith J, Druta M, Kis B. Liver-directed treatments of liver-dominant metastatic leiomyosarcoma. Diagn Interv Radiol. 2020 Sep.26(5):449-455. Pubmedid: 32673206. Pmcid: PMC7490031.
Somaiah N, Chawla SP, Block MS, Morris JC, Do K, Kim JW, Druta M, Sankhala KK, Hwu P, Jones RL, Gnjatic S, Kim-Schulze S, Tuballes K, Yishak M, Lu H, Yakovich A, Ter Meulen J, Chen M, Kenney RT, Bohac C, Pollack SM. A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1. Oncoimmunology. 2020 Nov.9(1):1847846. Pubmedid: 33312760. Pmcid: PMC7714520.
Pollack SM, Somaiah N, Araujo DM, Druta M, Van Tine BA, Burgess MA, Chawla SP, Seetharam M, Okuno SH, Bohac C, Chen M, Yurasov S, Attia S. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020 Jul.9(13):4593-4602. Pubmedid: 32374488. Pmcid: PMC7333839.
Rizk VT, Naghavi AO, Brohl AS, Joyce DM, Binitie O, Kim Y, Hanna JP, Swank J, Gonzalez RJ, Reed DR, Druta M. Chemotherapy improves distant control in localized high-grade soft tissue sarcoma of the extremity/trunk. Clin Sarcoma Res. 2020 Jul.10:11. Pubmedid: 32670544. Pmcid: PMC7350709.
Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 Oct.7(1):276. Pubmedid: 31651363. Pmcid: PMC6813983.
Bridge JA, Sumegi J, Druta M, Bui MM, Henderson-Jackson E, Linos K, Baker M, Walko CM, Millis S, Brohl AS. Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019 Nov.32(11):1593-1604. Pubmedid: 31189996.
Pham V, Henderson-Jackson E, Doepker MP, Caracciolo JT, Gonzalez RJ, Druta M, Ding Y, Bui MM. Practical Issues for Retroperitoneal Sarcoma. Cancer Control. 2016 Jul.23(3):249-264. Pubmedid: 27556665.
Dossett LA, Toloza EM, Fontaine J, Robinson LA, Reed D, Druta M, Letson DG, Zager JS, Gonzalez RJ. Outcomes and clinical predictors of improved survival in a patients undergoing pulmonary metastasectomy for sarcoma. J Surg Oncol. 2015 Jul.112(1):103-106. Pubmedid: 26179670.
Liu JJ, Druta M, Shibata D, Coppola D, Boler I, Elahi A, Reich RR, Siegel E, Extermann M. Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?. Geriatr Oncol. 2014 Jan.5(1):40-48. Pubmedid: 24484717. Pmcid: PMC4527303.
Helm J, Centeno B, Coppola D, Druta M, Park J, Chen D, Hodul P, Kvols LK, Yeatman T, Carey L, Karl R, Malafa M. Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institution. Cancer Control. 2008 Oct.15(4):288-294. Pubmedid: 18813196.
Jacobsen PB, Shibata D, Siegel EM, Druta M, Lee JH, Marshburn J, Davenport L, Cruse H, Levine R, Gondi A, Brown R, Malafa M. Measuring quality of care in the treatment of colorectal cancer: the moffitt quality practice initiative. J Oncol Pract. 2007 Mar.3(2):60-65. Pubmedid: 20859375. Pmcid: PMC2793747.
Title: A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with Azacitidine in Patients with Recurrent, Resectable Osteosarcoma Sponsor: Florida Biomedical Research Program (FBRP) PI: Druta, M.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
patient privacy.
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
patient satisfaction.
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
